Ensartinib, sold under the brand name Ensacove, is an
anti-cancer medication
Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs ( chemotherapeutic agents or alkylating agents) in a standard regimen. Chemotherapy may be given with a cu ...
used for the treatment of
non-small cell lung cancer
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitiv ...
.
Ensartinib is an
Anaplastic lymphoma kinase
Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246) is an enzyme that in humans is encoded by the ''ALK'' gene.
Identification
Anaplastic lymphoma kinase (ALK) was originally di ...
(ALK) inhibitor used as the salt ensartinib hydrochloride.
It is taken
by mouth
Oral administration is a route of administration whereby a substance is taken through the Human mouth, mouth, swallowed, and then processed via the digestive system. This is a common route of administration for many medications.
Oral administ ...
.
The most common adverse reactions include rash, musculoskeletal pain, constipation, cough, pruritis, nausea, edema, pyrexia, and fatigue.
[ ]
Ensartinib was approved for medical use in the United States in December 2024.
Medical uses
Ensartinib is
indicated
In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis ...
for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.
History
Efficacy was evaluated in eXALT3 (NCT02767804), an open-label, randomized, active-controlled, multicenter trial in 290 participants with locally advanced or metastatic ALK-positive non-small cell lung cancer who had not previously received an ALK-targeted therapy.
Participants were randomized 1:1 to receive ensartinib or crizotinib.
Society and culture
Legal status
Ensartinib was approved for medical use in the United States in December 2024.
Names
Ensartinib is the
international nonproprietary name.
Ensartinib is sold under the brand name Ensacove.
References
External links
*
*
{{Authority control
Kinase inhibitors
Benzamides
Chlorobenzenes
Ethers
Fluorobenzenes
Piperazines
Pyridazines
Antineoplastic drugs